Anavex Life Sciences Corp
AVXL7.970USD
-0.060-0.75%
Fechamento 10/31, 16:00（ET）Cotações atrasadas em 15 min
680.73MValor de mercado
PerdaP/L TTM
Mais detalhes de Anavex Life Sciences Corp Empresa
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Informações de Anavex Life Sciences Corp
Código da empresaAVXL
Nome da EmpresaAnavex Life Sciences Corp
Data de listagemApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Número de funcionários42
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 13
Endereço630 5Th Avenue
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10111
Telefone18446893939
Sitehttps://www.anavex.com
Código da empresaAVXL
Data de listagemApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Executivos da empresa Anavex Life Sciences Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Outro
78.96%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Outro
78.96%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.94%
Investment Advisor/Hedge Fund
9.52%
Individual Investor
3.36%
Hedge Fund
3.04%
Research Firm
1.10%
Bank and Trust
0.83%
Pension Fund
0.21%
Insurance Company
0.04%
Outro
57.97%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
365
33.21M
38.67%
-1.68M
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
6.22M
7.24%
+237.96K
+3.98%
Jun 30, 2025
The Vanguard Group, Inc.
5.09M
5.92%
+204.62K
+4.19%
Jun 30, 2025
State Street Investment Management (US)
2.95M
3.43%
-265.45K
-8.26%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.02M
2.35%
+54.98K
+2.80%
Jun 30, 2025
Two Sigma Investments, LP
1.80M
2.09%
+428.37K
+31.31%
Jun 30, 2025
Missling (Christopher U)
1.51M
1.76%
+42.45K
+2.89%
Sep 11, 2025
Skarpelos (Athanasios)
1.31M
1.52%
--
--
Apr 25, 2025
Northwest Asset Management
1.02M
1.19%
+24.13K
+2.41%
Jun 30, 2025
Invesco Capital Management LLC
821.33K
0.96%
+306.26K
+59.46%
Jun 30, 2025
Northern Trust Investments, Inc.
715.06K
0.83%
+40.31K
+5.97%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Neuroscience and Healthcare ETF
1.32%
ALPS Medical Breakthroughs ETF
0.42%
SPDR S&P Biotech ETF
0.25%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Growth ETF
0.05%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção1.32%
ALPS Medical Breakthroughs ETF
Proporção0.42%
SPDR S&P Biotech ETF
Proporção0.25%
iShares Micro-Cap ETF
Proporção0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.14%
Vanguard US Momentum Factor ETF
Proporção0.1%
ProShares Ultra Nasdaq Biotechnology
Proporção0.08%
Invesco Nasdaq Biotechnology ETF
Proporção0.08%
iShares Biotechnology ETF
Proporção0.07%
iShares Russell 2000 Growth ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
